Les publications contenues dans cette section d’archives sont fournies à des fins historiques uniquement. Les opinions présentées dans les publications sont celles de leurs auteurs et ne reflètent pas les opinions de NOXXON. NOXXON rejette toute obligation de mise à jour ou de correction des informations contenues dans ces articles.

Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Więcek A, Haller H.
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.
Nephrol Dial Transplant. 2016.
read article on oxfordjournals.org

Hoehlig K, Klussmann S.
Spiegelbildliche Nukleinsäuren als pharmakologische Wirkstoffe.
Chemie in unserer Zeit 2015, 49(6), 422-5.
read abstract on wiley.com

Hoehlig K, Klussmann S.
Korrespondenz:
Molekulare Schere.

Chemie in unserer Zeit
2015, 49(6), 421.
read abstract on wiley.com

Kalnins A, Thomas MN, Andrassy M, Müller S, Wagner A, Pratschke S, Rentsch M, Klussmann S, Kauke T, Angele MK, Bazhin AV, Fischereder M, Werner J, Guba M, Andrassy J.
Spiegelmer Inhibition of MCP-1/CCR2 - Potential as an Adjunct Immunosuppressive Therapy in Transplantation.
Scand J Immunol. 2015, 82(2), 102.
read abstract on pubmed.gov

Brockmann C, Brockmann T, Dege S, Busch C, Kociok N, Vater A, Klussmann S, Strauß O, Joussen AM.
Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice.
Graefes Arch Clin Exp Ophthalmol. 2015.
read abstract on pubmed.gov

Oberthür D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders D, Klussmann S, Betzel C.
Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.
Nature Commun. 2015, 6, 6923.
read article on nature.com

Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater A.
Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA/L-DNA aptamer.
Nature Commun. 2015, 6, 6481.
read article on nature.com

Mavroidis M, Davos CH, Psarras S, Varela A, C Athanasiadis N, Katsimpoulas M, Kostavasili I, Maasch C, Vater A, van Tintelen JP, Capetanaki Y.
Complement system modulation as a target for treatment of arrhythmogenic cardiomyopathy.
Basic Res Cardiol. 2015, 110(3), 485.
read abstract on pubmed.gov

Haller H, Menne J, Baumann M, Eulberg D.
CCL2 Inhibition with Emapticap Pegol (NOX-E36) in Type 2 Diabetic Patients with Albuminuria.

ISN World Congress of Nephrology
2015, Cape Town
Poster

Benedetti E, Duchemin N, Bethge L, Vonhoff S, Klussmann S, Vasseur JJ, Cossy J, Smietana M, Arseniyadis S.
DNA-cellulose: an economical, fully recyclable and highly effective chiral biomaterial for asymmetric catalysis.
Chem. Comm. 2015, 51(28), 6076-9.
read abstract on pubmed.gov

Hoehlig K, Bethge L, Klussmann S.
Stereospecificity of Oligonucleotide Interactions Revisited: No Evidence for Heterochiral Hybridization and Ribozyme/DNAzyme Activity.
PLoS One. 2015, 10(2), e0115328.
read abstract on pubmed.gov

Hoehlig K, Johnson KW, Pryazhnikov E, Maasch C, Clemens-Smith A, Purschke W, Vauléon S, Buchner K, Jarosch F, Khiroug L, Vater A, Klussmann S.
A Novel CGRP-neutralizing Spiegelmer Attenuates Neurogenic Plasma Protein Extravasation.
Br.J.Pharmacol. 2015.
read abstract on wiley.com

Vater A, Klussmann S.
Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer therapeutics.
Drug Discovery Today. 2015, 20(1), 147-155.
read article on sciencedirect.com